Skip to content

Lexicon Pharma buy reiterated by Needham, target $21

April 10, 2017

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Wednesday. They currently have a $21.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s target price suggests a potential upside of 53.28% from the stock’s current price.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: